REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Peptide Therapy Shows Promise During Ramadan for Type 2 Diabetes
Back to Research Library

Peptide Therapy Shows Promise During Ramadan for Type 2 Diabetes

May 25, 2026
Share
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article is an AI-assisted summary of a recently published news item or clinical trial listing. It is intended to provide a quick, accessible overview for the peptide research community. For full accuracy, always refer to the original source linked below.

Peptide Therapy Shows Promise During Ramadan for Type 2 Diabetes

A groundbreaking study conducted by Eli Lilly and Company has concluded that a novel peptide therapy, tirzepatide (LY3298176), can effectively manage type 2 diabetes in patients who observe the month-long Islamic fast of Ramadan. This research offers hope to millions around the world who struggle with balancing their health needs during religious observances.

Background

Ramadan is a holy month for Muslims, during which fasting occurs from dawn until sunset. For individuals managing chronic conditions like type 2 diabetes, this period presents unique challenges as it can disrupt routine medication schedules and dietary habits. Traditionally, patients have had to adjust their insulin and other treatments, often leading to fluctuations in blood glucose levels. The introduction of tirzepatide offers a new avenue for maintaining stable blood sugar levels without the need for significant adjustments.

Tirzepatide is a dual GIP and GLP-1 receptor agonist that has already shown efficacy in managing type 2 diabetes by improving glycemic control, reducing body weight, and lowering cardiovascular risk factors. The study's completion marks an important milestone in understanding how this peptide therapy can be utilized during periods of fasting.

Key Details

The completed clinical trial, NCT06635057, was designed to assess the safety and efficacy of initiating tirzepatide before Ramadan and continuing it throughout the month. The study included participants with type 2 diabetes who were eligible for Ramadan fasting based on their medical condition.

Researchers found that participants who used tirzepatide maintained stable blood glucose levels without the need for significant dietary adjustments or additional medications commonly required during fasting periods. This outcome is a critical step in confirming the viability of peptide therapies as effective management tools during religious observances and other situations where traditional treatment approaches may be less practical.

Key Takeaways

  • Effective Management: Tirzepatide can help maintain stable blood glucose levels for individuals with type 2 diabetes who fast.
  • No Dietary Adjustments Needed: Patients using tirzepatide did not require major changes to their diet during Ramadan, simplifying management of the condition.
  • Safety and Efficacy: The study confirmed that initiating treatment before fasting periods and continuing it throughout provides a consistent level of control over blood sugar levels.
  • Clinical Validation: This research adds significant clinical data to the growing body of evidence supporting peptide therapy in managing type 2 diabetes.

What This Means

The results of this study highlight the potential for peptide therapies like tirzepatide to offer flexible and effective solutions for patients with chronic conditions who face unique challenges during religious observances or other fasting periods. As more research continues, these findings could pave the way for broader applications of peptide-based treatments in managing type 2 diabetes and potentially other metabolic disorders.

For the peptide community, this study underscores the importance of ongoing clinical trials and regulatory oversight to ensure that innovative therapies like tirzepatide can be safely and effectively integrated into patient care plans. It also emphasizes the need for continued research into how such treatments perform under various conditions and lifestyles.

---

Source: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06635057) — Published 2026-05-22

This article is for informational purposes only and does not constitute medical advice.

Editor's Note

This analysis was generated using AI tools and reviewed by the Peptide Contacts editorial team. While we strive for accuracy, AI-generated content may contain errors or omissions. We encourage readers to review the original source for complete details, methodology, and data.

Peptide Contacts provides curated research summaries for informational purposes only. This content does not constitute medical advice. Always consult a qualified healthcare provider before making any health decisions.

Comments

Sign in to join the discussion

This article was generated using AI and may contain inaccuracies. It is provided for informational purposes only and does not constitute medical advice. Always verify information with the original source and consult a qualified healthcare provider before making any health decisions.